Podcast: Key takeaways from EASD 2026 on where GLP-1s are headed
Experts discuss the latest research released at EASD 2026 and what it could mean for the diabetes community.
Therapy Area
GLP-1RA non-responders: tackling a hidden challenge behind the obesity epidemic
AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact
Novartis bets on autoimmune BiTEs through $7.8bn Abogen deal
Varda pockets $251m to back space-based pharma processing mission
EASD 2026: Tirzepatide outperforms semaglutide in real-world type 2 diabetes analysis
Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab
EASD 2026: Orforglipron shows an efficacy edge over oral semaglutide in T2D
